Blast­ing 'spec­u­la­tive com­men­tary,' GSK of­fers up­date on Zan­tac lit­i­ga­tion and vows to 'vig­or­ous­ly de­fend it­self'

GSK wants to ad­dress “spec­u­la­tive com­men­tary” about its Zan­tac lit­i­ga­tion head on.

The phar­ma gi­ant put out a lengthy state­ment af­ter a suite of an­a­lysts …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER